Varicella-zoster virus-specific antibody responses in 50-59-year-old recipients of zoster vaccine.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Journal of Infectious Diseases

• Publication date

  2013-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/infdis/jit342PMID 23908486PMCID PMC4550114
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A community-based survey of varicella-zoster virus-specific immune responses in the elderly.

  2012cited by this paper
• Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years.

  2012cited by this paper
• Influence of age and nature of primary infection on varicella-zoster virus-specific cell-mediated immune responses.

  2010influential reference
• Zoster vaccine: current status and future prospects.

  2010cited by this paper
• Letter to the Editor Immune Response to a Refrigerator-Stable Zoster Vaccine

  2009cited by this paper
• Immune Response to a Refrigerator-Stable Zoster Vaccine

  2009cited by this paper
• A real‐time PCR assay to identify and discriminate among wild‐type and vaccine strains of varicella‐zoster virus and herpes simplex virus in clinical specimens, and comparison with the clinical diagnoses

  2009influential reference
• Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine.

  2008cited by this paper
• Measurement of varicella-zoster virus (VZV)-specific cell-mediated immunity: comparison between VZV skin test and interferon-gamma enzyme-linked immunospot assay.

  2008cited by this paper
• Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP).

  2008influential reference
• A Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older Adults

  2007influential reference
• The optimization and validation of the glycoprotein ELISA assay for quantitative varicella‐zoster virus (VZV) antibody detection

  2006cited by this paper
• Safety, tolerability, and immunogenicity of a two-dose regimen of high-titer varicella vaccine in subjects > or =13 years of age.

  2006cited by this paper
• Relationship between Preexisting Anti-Varicella-Zoster Virus (VZV) Antibody and Clinical VZV Reactivation in Hematopoietic Stem Cell Transplantation Recipients

  2006cited by this paper
• Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP).

  2005cited by this paper
• Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants.

  2002cited by this paper
• Racial differences in the occurrence of herpes zoster.

  1995cited by this paper
• Cellular and humoral immunity in the pathogenesis of recurrent herpes viral infections in patients with lymphoma.

  1980cited by this paper

• Safety and immunogenicity of the recombinant zoster vaccine (LZ901) against herpes zoster in Chinese old people: A phase I trial

  2026cites this paper
• Immunogenicity and safety of a recombinant gE-Fc fusion protein subunit vaccine for herpes zoster in adults ≥50 years of age: a randomised, active-controlled, non-inferiority trial

  2025cites this paper
• A replication-deficient gammaherpesvirus vaccine protects mice from lytic disease and reduces latency establishment

  2024cites this paper
• Replication-dead gammaherpesvirus vaccine protects against acute replication, reactivation from latency, and lethal challenge in mice

  2023cites this paper
• Le zona – Partie 3 : la prévention du zona et des névralgies post-zostériennes

  2023cites this paper
• Prophylactic vaccination with a live-attenuated herpes zoster vaccine in lung transplant candidates.

  2020cites this paper
• Immunogenicity of Inactivated Varicella Zoster Vaccine in Autologous Hematopoietic Stem Cell Transplant Recipients and Patients With Solid or Hematologic Cancer

  2020cites this paper
• Herpes Zoster Vaccines

  2019cites this paper
• Vaccination for quality of life: herpes–zoster vaccines

  2019cites this paper
• Towards strengthening memory immunity in the ageing population: Investigating the immunological fitness of middle-aged adults

  2018cites this paper
• Safety and Immunogenicity of Zoster Vaccine Live in Human Immunodeficiency Virus–Infected Adults With CD4+ Cell Counts >200 Cells/mL Virologically Suppressed on Antiretroviral Therapy

  2018cites this paper
• Low Rates of Vaccination for Herpes Zoster in Older People Living With HIV

  2018cites this paper
• Age-Dependent Pre-Vaccination Immunity Affects the Immunogenicity of Varicella Zoster Vaccination in Middle-aged Adults

  2018cites this paper
• Breadth and Functionality of Varicella-Zoster Virus Glycoprotein-Specific Antibodies Identified after Zostavax Vaccination in Humans

  2018cites this paper
• A randomized, placebo‐controlled phase I trial of live, attenuated herpes zoster vaccine in subjects with end‐stage renal disease immunized prior to renal transplantation

  2018cites this paper
• Immunogenicity and safety of zoster vaccine live administered with quadrivalent influenza virus vaccine.

  2018cites this paper
• Immunogenicity, Safety, and Tolerability of Live Attenuated VaricellaZoster Virus Vaccine (ZOSTAVAX™) in Healthy Adults in India.

  2018cites this paper
• Efficacy, effectiveness, and safety of herpes zoster vaccines in adults aged 50 and older: systematic review and network meta-analysis

  2018cites this paper
• High Constitutive Interleukin 10 Level Interferes With the Immune Response to Varicella-Zoster Virus in Elderly Recipients of Live Attenuated Zoster Vaccine

  2018cites this paper
• Association between quantitative varicella-zoster virus antibody levels and zoster reactivation in HIV-infected persons

  2018cites this paper
• 65 – Zoster Vaccines

  2018cites this paper
• Herpes Zoster in Patients Receiving JAK Inhibitors For Ulcerative Colitis: Mechanism, Epidemiology, Management, and Prevention

  2018cites this paper
• Clinical Usage of the Adjuvanted Herpes Zoster Subunit Vaccine (HZ/su): Revaccination of Recipients of Live Attenuated Zoster Vaccine and Coadministration With a Seasonal Influenza Vaccine.

  2017cites this paper
• Safety and Immunogenicity of Inactivated Varicella-Zoster Virus Vaccine in Adults With Autoimmune Disease: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Clinical Trial

  2017cites this paper
• Is chickenpox so bad, what do we know about immunity to varicella zoster virus, and what does it tell us about the future?

  2017cites this paper
• The Safety and Immunogenicity of Live Zoster Vaccination in Patients With Rheumatoid Arthritis Before Starting Tofacitinib: A Randomized Phase II Trial

  2017influential citation
• A randomized lot-to-lot immunogenicity consistency study of the candidate zoster vaccine HZ/su.

  2017cites this paper
• [Vaccines against Herpes zoster: Effectiveness, safety, and cost/benefit ratio].

  2016cites this paper
• Immune response and reactogenicity of intradermal administration versus subcutaneous administration of varicella-zoster virus vaccine: an exploratory, randomised, partly blinded trial.

  2016cites this paper
• Cellular and Humoral Responses to a Second Dose of Herpes Zoster Vaccine Administered 10 Years After the First Dose Among Older Adults.

  2016cites this paper
• Shingles (Herpes Zoster) Vaccine (Zostavax®): A Review in the Prevention of Herpes Zoster and Postherpetic Neuralgia

  2016cites this paper
• Varicella Zoster Virus: A Common Cause of Stroke in Children and Adults.

  2016cites this paper
• Les vaccins contre le zona : efficacité, sécurité, et rapport coût/bénéfices

  2016cites this paper
• Comparison of intramuscular and subcutaneous administration of a herpes zoster live-attenuated vaccine in adults aged ≥50 years: a randomised non-inferiority clinical trial.

  2015cites this paper
• Zoster Vaccination Increases the Breadth of CD4+ T Cells Responsive to Varicella Zoster Virus.

  2015cites this paper
• Herpes zoster is associated with herpes simplex and other infections in under 60 year-olds.

  2015cites this paper
• Fold rise in antibody titers by measured by glycoprotein-based enzyme-linked immunosorbent assay is an excellent correlate of protection for a herpes zoster vaccine, demonstrated via the vaccine efficacy curve.

  2014cites this paper
• Evaluación de la vacuna para la prevención del herpes zóster en adultos: revisión sistemática de la literatura

  2014cites this paper
• Influence of Frequent Infectious Exposures on General and Varicella-Zoster Virus-Specific Immune Responses in Pediatricians

  2014cites this paper